Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Milton S. Hershey Medical Center
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Virginia
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
Barbara Ann Karmanos Cancer Institute
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Washington University School of Medicine
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
University of South Florida
National Cancer Institute (NCI)
Vanderbilt University
Children's Oncology Group
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Duke University
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
Neotropix